$235 Million is the total value of TCG Crossover Management, LLC's 22 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CBAY | CymaBay Therapeutics, Inc. | $17,421,000 | -5.1% | 5,905,400 | 0.0% | 7.40% | +0.4% | |
| ACRS | Aclaris Therapeuitics, Inc. | $15,983,000 | -19.0% | 1,144,939 | 0.0% | 6.79% | -14.3% | |
| VRDN | Viridian Therapeutics Inc | $15,203,000 | -37.4% | 1,314,000 | 0.0% | 6.46% | -33.8% | |
| AVTE | Aerovate Therapeutics, Inc. | $13,904,000 | -14.7% | 889,572 | 0.0% | 5.91% | -9.8% | |
| Entrada Therapeutics, Inc. | $8,084,000 | +31.8% | 663,694 | 0.0% | 3.43% | +39.5% | ||
| MRUS | Merus N.V. | $6,792,000 | -14.4% | 300,000 | 0.0% | 2.88% | -9.4% | |
| Tyra Biosciences, Inc. | $6,409,000 | -33.2% | 896,418 | 0.0% | 2.72% | -29.3% | ||
| AKUS | Akouos, Inc. | $6,332,000 | -1.3% | 1,350,006 | 0.0% | 2.69% | +4.5% | |
| ZLAB | Zai Lab LTD-ADR | $3,295,000 | -21.1% | 95,000 | 0.0% | 1.40% | -16.5% | |
| MGTA | Magenta Therapeutics, Inc. | $2,549,000 | -58.6% | 2,124,122 | 0.0% | 1.08% | -56.2% | |
| ANAB | AnaptysBio, Inc. | $1,188,000 | -18.0% | 58,515 | 0.0% | 0.50% | -13.1% | |
| ELEV | Elevation Oncology, Inc. | $777,000 | -44.5% | 555,000 | 0.0% | 0.33% | -41.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
| AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
| TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
| ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
| MERUS N.V. | 8 | Q3 2023 | 3.4% |
| IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
| Geron Corporation | 7 | Q3 2023 | 12.4% |
| ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
| KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
| CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
| Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
| Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
| Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| SC 13G | 2022-08-19 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.